On September 18, 2025, FDA's Center for Tobacco Products launched the Nicotine Pouch PMTA Pilot: a streamlined review process designed to accelerate authorization decisions for the top nicotine pouch brands in the US market. Six months later, the pilot stalled. On April 1, 2026, Reuters reported that the program is being scrapped.
The pilot produced one authorized product line before collapsing: six on! PLUS nicotine pouches from Altria's Helix Innovations, cleared December 19, 2025. Applications for ZYN (Philip Morris International), Velo (BAT/Reynolds), and brands from Turning Point Brands remain in review with no defined timeline. The $22 billion US market for smoking alternatives is waiting.
For nicotine ingredient suppliers and the manufacturers they supply, the pilot's cancellation has a direct consequence. The documentation relaxations the pilot introduced are gone. Full PMTA review under 21 CFR Part 1114 is the only pathway. Based on ZYN's track record, that pathway runs close to five years.
What the PMTA Fast-Track Pilot Was, and What Changed When It Launched
The Nicotine Pouch PMTA Pilot targeted a specific problem: reviews for nicotine pouch applications had been pending for years, and FDA needed a more efficient process for evaluating them at category scale. The pilot applied to a defined set of manufacturers: PMI for ZYN, BAT and Reynolds for Velo, Turning Point Brands for Fre and ALP, and Altria's Helix Innovations for on! PLUS.
The key documentation change was in the behavioral and consumer perception endpoints. Under standard PMTA review, manufacturers typically need product-specific studies covering consumer switching behavior, cigarettes-per-day reduction, and consumer perception of relative risk. The pilot allowed applicants to rely on category-wide scientific literature for those endpoints rather than conducting product-specific studies.
What the pilot did not waive: product-specific Harmful and Potentially Harmful Constituents (HPHC) yield data, pharmacokinetics (PK) delivery data, and abuse liability data. Those requirements remained fully in place.
The goal was to complete reviews for all included applications by the end of 2025.
Why the Pilot Stalled
FDA scientists were not satisfied that the pilot's streamlined approach produced sufficient evidence for the remaining applications.
Reuters, reporting on April 1, 2026 from sources familiar with the review, cited two primary concerns. First, FDA scientists flagged the risk of nicotine addiction among adults who do not already smoke, a harm category that complicates the harm reduction case. Second, the ZYN and Velo applications were viewed as having less clear evidence of net public health benefit compared to the on! PLUS products that were authorized in December 2025.
The on! PLUS applications cleared: six products (Mint, Tobacco, and Wintergreen in both 6 mg and 9 mg) received marketing authorization on December 19, 2025. Everything else stalled.
Total FDA-authorized nicotine pouch products as of early 2026: 26 products. That count includes 20 ZYN products authorized January 16, 2025, and the 6 on! PLUS products. All other nicotine pouches on the US market remain without marketing authorization.
As of April 4, 2026, FDA has not announced a replacement program or a revised timeline for applications that were in the pilot pipeline.
What Full PMTA Review Under 21 CFR Part 1114 Actually Requires
The governing framework for PMTA submissions is 21 CFR Part 1114. The controlling legal standard is the APPH standard: a product must be shown to be "appropriate for the protection of public health" under Section 910(c)(2) of the Federal Food, Drug, and Cosmetic Act. The pilot did not change this standard. Its cancellation does not change it either. What changes is the evidentiary path to meeting it.
Under full PMTA review, the relaxations the pilot introduced are no longer available. Manufacturers must provide product-specific studies for behavioral and consumer perception endpoints. Category-level literature bridging is not a substitute.
The timeline precedent is critical for planning. ZYN's PMTA was submitted in March 2020. FDA authorization came on January 16, 2025, nearly five years later. A 2023 FDA Office of Inspector General report found that CTP failed to issue orders within the statutory 180-day review deadline in multiple ENDS PMTA cases. For manufacturers with pending applications, a multi-year review period is the realistic planning assumption.
One additional requirement took effect January 2, 2026: all PMTA and Substantial Equivalence (SE) submissions must use FDA's web-based application forms. Applications submitted in outdated formats are subject to Refuse to Accept (RTA). Any manufacturer updating its application package must be working in the new format.
What This Means for Your Nicotine Ingredient Documentation
When a PMTA moves to full standard review, every ingredient must be documented to FDA's satisfaction. For nicotine, the primary active ingredient, that documentation package typically includes the following components.
Purity and grade specifications. FDA expects USP/EP grade nicotine as the documentation standard in PMTA ingredient submissions. The Certificate of Analysis (CoA) must include grade certification, assay percentage, and full impurity profile. Batch-level CoA documentation is the standard for traceability purposes.
HPHC characterization. The nicotine ingredient's contribution to the finished product's HPHC profile must be documentable. This includes Tobacco Specific Nitrosamines (TSNAs) and any carbonyls or other HPHCs relevant to the specific product format.
Stability data. The PMTA must demonstrate that ingredient specifications are maintained through the product's shelf life. Stability data for the nicotine ingredient, at the specifications supplied, is part of that package.
Pharmacokinetics and abuse liability. These were not waived under the pilot and remain required under the standard pathway. Nicotine salts formulated for pouch delivery have distinct PK profiles depending on the specific salt form. Product-specific PK delivery data and abuse liability assessments are expected in the application. Category-level literature does not satisfy these requirements under the standard pathway.
Manufacturing GMP documentation. FDA requires that the supplier's manufacturing site operate under GMP practices. Documentation of GMP certification and audit history for the manufacturing partner supports the manufacturer's ability to demonstrate consistent ingredient quality across production batches.
Tobacco Product Master Files (TPMFs). A TPMF is a confidential FDA submission containing the supplier's proprietary ingredient and composition data. Manufacturers cross-reference a TPMF in their PMTA, satisfying ingredient documentation requirements without requiring the supplier to disclose trade secrets to the applicant or the public. A supplier with a current, comprehensive TPMF on file substantially reduces manufacturer documentation burden. A supplier without one forces the manufacturer to independently document all ingredient details, typically with less precision and no confidentiality protection for the supplier's formulations.
Why US-Sourced Nicotine Changes the Compliance Calculation
Supply chain documentation is a structural component of the PMTA. The sourcing decision has regulatory consequences, not just procurement ones.
A US-based supply chain with a certified manufacturing partner simplifies the documentation trail in concrete ways. Import documentation complexity is eliminated. Response time to FDA requests for additional information is faster. Manufacturing partner audits are accessible on shorter notice. During a multi-year review, FDA routinely issues requests for supplemental information. The ability to respond quickly with verifiable documentation is part of what shapes how reviews go.
The contrast with unverified offshore sourcing is consequential. Supply chain traceability from raw material origin through final delivery is a component of the PMTA's ingredient documentation standards. For manufacturers relying on offshore suppliers without comprehensive documentation programs, building that traceability retroactively during an active review is a material liability.
The post-pilot environment raises the stakes on this decision. FDA's stated concerns about product-specific evidence extend to the entire evidentiary package. Ingredient documentation quality is not peripheral to that evaluation. Sourcing from a supplier that can pre-position documentation support, offer TPMF cross-reference capability, and maintain an audit-ready supply chain is a risk management decision.
For a full breakdown of how nicotine sourcing decisions interact with PMTA submission requirements, see PMTA Requirements: How Your Nicotine Source Affects FDA Submissions.
Five Questions to Ask Your Nicotine Supplier Right Now
The pilot's cancellation creates an immediate documentation review opportunity for any manufacturer with a pending PMTA or one in development. These questions will surface gaps before FDA does.
- Do you have an active Tobacco Product Master File (TPMF) on file with FDA, and can you grant us right of reference for our PMTA?
- What grade certifications (USP/EP) are included in your CoA, and can you provide batch-level impurity profiling for each lot?
- Can you provide HPHC characterization data for your nicotine ingredient as supplied, at the specifications relevant to our product format?
- What documentation covers your manufacturing partner's GMP status, certification history, and audit records?
- Can you support our PMTA with full supply chain traceability documentation from raw material origin through final delivery?
A supplier that cannot answer these questions with specific documentation is a compliance risk in the current regulatory environment.
Frequently Asked Questions
What was the FDA PMTA fast-track pilot, and why was it canceled in April 2026?
FDA's Center for Tobacco Products launched the Nicotine Pouch PMTA Pilot on September 18, 2025 to streamline reviews for a defined set of major-brand nicotine pouch applications. The pilot allowed manufacturers to use category-wide scientific literature for certain behavioral and consumer perception endpoints rather than conducting product-specific studies. It was designed to complete all reviews by end of 2025. By April 2026, the program had stalled: only six on! PLUS products received authorization in December 2025. Reuters reported on April 1, 2026 that FDA scientists raised concerns about the risk of nicotine addiction among adults who do not already smoke, and about the adequacy of remaining applications' public health benefit evidence. As of April 4, 2026, FDA has not announced a replacement program.
My PMTA application was in the pilot pipeline. What happens to it now?
Applications that were in the pilot pipeline remain under review but without a defined fast-track timeline. They revert to the standard PMTA review process governed by 21 CFR Part 1114, with the APPH standard controlling. Based on historical precedent, ZYN's application took nearly five years from submission (March 2020) to authorization (January 2025). A 2023 FDA OIG report found CTP routinely missed the statutory 180-day review deadline for ENDS products. Extended multi-year review timelines should be treated as the baseline planning assumption.
What nicotine ingredient documentation do I need to support a post-pilot PMTA submission?
At minimum: a Certificate of Analysis covering USP/EP grade purity, full impurity profile, and batch-level identification; HPHC characterization data including Tobacco Specific Nitrosamines (TSNAs); product-specific pharmacokinetics (PK) delivery data and abuse liability data (these were never waived under the pilot); stability data demonstrating specifications are maintained through shelf life; and manufacturing site GMP documentation. A supplier-maintained Tobacco Product Master File (TPMF) that you cross-reference in your PMTA can satisfy ingredient documentation requirements without requiring suppliers to disclose proprietary formulations.
Does my nicotine supplier need a Tobacco Product Master File (TPMF) on file with FDA?
A TPMF is not legally required, but it is strategically significant. A TPMF allows the supplier to submit confidential ingredient and composition data directly to FDA. The manufacturer cross-references it in the PMTA without the supplier's proprietary data being disclosed to the applicant or the public. This protects supplier IP while giving the PMTA a stronger, more defensible documentation foundation. Without a supplier TPMF, manufacturers must document all ingredient details themselves or negotiate direct data sharing arrangements, typically with less precision and less IP protection for both parties.
The pilot is gone. FDA has not announced what comes next, and no timeline exists for the applications that remain in review.
For manufacturers with pending PMTAs, a reasonable planning horizon is three to five years based on the ZYN precedent, with no guarantee of a faster path becoming available. The companies that emerge from this period with authorized products will be the ones whose documentation packages were already audit-ready before FDA came back with questions. That preparation starts with the ingredient supply chain, and it starts now. NicAlliance provides USP/EP grade nicotine with full documentation support for PMTA submissions, backed by a certified US-based supply chain.
If this was useful, there's more where it came from.
Industry intelligence for nicotine product manufacturers. No fluff.